Atria Investments Inc Reduces Stock Position in Glaukos Co. (NYSE:GKOS)

Atria Investments Inc lowered its position in Glaukos Co. (NYSE:GKOS) by 14.9% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 6,024 shares of the medical instruments supplier’s stock after selling 1,056 shares during the period. Atria Investments Inc’s holdings in Glaukos were worth $785,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Values First Advisors Inc. acquired a new stake in shares of Glaukos in the third quarter worth $25,000. GAMMA Investing LLC grew its position in Glaukos by 68.8% during the 2nd quarter. GAMMA Investing LLC now owns 1,192 shares of the medical instruments supplier’s stock worth $141,000 after purchasing an additional 486 shares during the period. Fifth Third Wealth Advisors LLC purchased a new position in shares of Glaukos during the 2nd quarter valued at about $187,000. Procyon Advisors LLC acquired a new position in shares of Glaukos in the 3rd quarter valued at about $210,000. Finally, Brighton Jones LLC purchased a new position in Glaukos during the second quarter valued at approximately $208,000. Institutional investors and hedge funds own 99.04% of the company’s stock.

Wall Street Analyst Weigh In

GKOS has been the topic of a number of analyst reports. StockNews.com raised shares of Glaukos from a “sell” rating to a “hold” rating in a research note on Monday, October 21st. Wells Fargo & Company raised their price target on shares of Glaukos from $135.00 to $145.00 and gave the company an “overweight” rating in a research report on Tuesday, November 5th. BTIG Research upped their price objective on shares of Glaukos from $131.00 to $139.00 and gave the stock a “buy” rating in a research report on Wednesday, August 28th. Needham & Company LLC raised their target price on Glaukos from $131.00 to $137.00 and gave the company a “buy” rating in a research report on Thursday, August 1st. Finally, Stifel Nicolaus lifted their price target on Glaukos from $130.00 to $145.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Four research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $134.55.

Insider Transactions at Glaukos

In other Glaukos news, Director Gilbert H. Kliman sold 3,000 shares of Glaukos stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $130.67, for a total transaction of $392,010.00. Following the transaction, the director now directly owns 32,336 shares of the company’s stock, valued at $4,225,345.12. The trade was a 8.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Joseph E. Gilliam sold 5,000 shares of the stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $129.36, for a total transaction of $646,800.00. Following the completion of the sale, the chief operating officer now directly owns 102,169 shares of the company’s stock, valued at approximately $13,216,581.84. This trade represents a 4.67 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 10,275 shares of company stock worth $1,354,967 in the last ninety days. Insiders own 6.40% of the company’s stock.

Glaukos Stock Down 1.2 %

Shares of GKOS opened at $136.79 on Tuesday. The stock has a 50 day moving average price of $130.92 and a 200 day moving average price of $122.57. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54. The stock has a market capitalization of $7.54 billion, a price-to-earnings ratio of -45.36 and a beta of 1.02. Glaukos Co. has a one year low of $59.22 and a one year high of $145.84.

Glaukos (NYSE:GKOS) last issued its earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.20. Glaukos had a negative net margin of 42.43% and a negative return on equity of 18.99%. The business had revenue of $96.70 million during the quarter, compared to analysts’ expectations of $91.50 million. During the same period in the prior year, the business earned ($0.50) earnings per share. The company’s quarterly revenue was up 23.9% compared to the same quarter last year. Equities research analysts forecast that Glaukos Co. will post -1.96 earnings per share for the current fiscal year.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.